Reuters logo
BRIEF-Roche gains CE label expansion for pd-l1 testing in lung and bladder cancers
September 28, 2017 / 2:16 PM / 24 days ago

BRIEF-Roche gains CE label expansion for pd-l1 testing in lung and bladder cancers

Sept 28 (Reuters) - Roche Holding Ag:

* Roche gains CE label expansion for pd-l1 testing in lung and bladder cancers in markets where tecentriq is approved

* Roche -will continue to pursue global regulatory approvals for pd-l1 (sp142) assay in combination with tecentriq for additional cancer indications Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below